Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 81, Issue 8, Pages 631-633Publisher
WILEY-LISS
DOI: 10.1002/ajh.20671
Keywords
chronic lymphocytic leukemia; autoimmune hemolytic anemia; rituximab
Categories
Ask authors/readers for more resources
The most frequent autoimmune complication in chronic lymphocytic leukemia (CLL) is autoimmune hemolytic anemia (AIHA). There are various treatment modalities; however. there is not much experience with the use of the chimeric anti-CD20 monoclonal antibody rituximab in the autoimmune complications of CLL. Here, we present our patient with CLL and AIHA whose ANA was unresponsive to various treatment modalities. The administration of 375 mg/m(2)/day rituximab weekly for four cycles halted hemolysis and resulted in resolution of the patient's anemia. One year after therapy, the patient is well with a normal blood count. Rituximab might be preferred over other treatment modalities in the autoimmune complications of CLL because it is effective and has fewer side effects than other therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available